Clinical Trial

AB-1002 in Patients With Class III Heart Failure

Study acronym: NAN-CS101
Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. 11 participants with non-ischemic cardiomyopathy were enrolled. All participants were followed until 12 months post treatment intervention, and then underwent long-term follow-up via semi-structured telephone questionnaires every 6 months for an additional 24 months (+/- 30 days).
Protocol Amendment History 3 changes
critical Trial completed 2026-08-07
notable Enrollment reduced: 17 -> 11 participants 2026-08-07
minor Completion moved earlier: 2026-09-30 -> 2026-07-23 2026-08-07
Trial Details
NCT Number NCT04179643
Lead Sponsor AskBio Inc
Conditions Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure，Congestive, Heart Arrhythmia, Heart Failure, Diastolic +1 more
Enrollment 11 participants
Start Date 2019-11-20
Primary Completion 2024-08-20 (estimated)
Study Completion 2026-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-06